{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:59:27Z","timestamp":1761742767540},"reference-count":33,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3387,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.00986.x","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T11:31:12Z","timestamp":1148470272000},"page":"745-751","source":"Crossref","is-referenced-by-count":53,"title":["Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial"],"prefix":"10.1155","volume":"60","author":[{"given":"V.","family":"ELINOFF","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"BAVENDAM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. B.","family":"GLASSER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"CARLSSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"EYLAND","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"ROBERTS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2006,5,24]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0149-2918(01)80104-1","article-title":"Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder","volume":"23","author":"Ricci","year":"2001","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB4|cit4","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB7|cit7","first-page":"26","article-title":"Overactive bladder. Strategies for better recognition and management","volume":"12","author":"Smith","year":"2004","journal-title":"Adv Nurse Pract"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/fampra\/cmh622","article-title":"What prevents older people from seeking treatment for urinary incontinence? A qualitative exploration of barriers to the use of community continence services","volume":"21","author":"Horrocks","year":"2004","journal-title":"Fam Pract"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/bmj.297.6657.1187","article-title":"Distress and delay associated with urinary incontinence, frequency, and urgency in women","volume":"297","author":"Norton","year":"1988","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB10|cit10","first-page":"602","article-title":"Urinary incontinence. Non-surgical management by family physicians","volume":"49","author":"Moore","year":"2003","journal-title":"Can Fam Physician"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0302-2838(02)00014-3","article-title":"Prevalence and physician awareness of symptoms of urinary bladder dysfunction","volume":"41","author":"Goepel","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3949\/ccjm.72.2.149","article-title":"Overactive bladder: evaluation and management in primary care","volume":"72","author":"Rosenberg","year":"2005","journal-title":"Cleve Clin J Med"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB13|cit13","first-page":"56","article-title":"The overactive bladder: an overview for primary care health providers","volume":"44","author":"Wein","year":"1999","journal-title":"Int J Fertil Womens Med"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nau.20110","article-title":"Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ)","volume":"24","author":"Matza","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB15|cit15","first-page":"83","article-title":"Patient perception of bladder condition is a valid tool for evaluating the efficacy of overactive bladder therapy","volume":"13","author":"Coyne","year":"2002","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1742-1241.2006.00987.x","article-title":"Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial","volume":"60","author":"Roberts","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0149-2918(02)85137-2","article-title":"A multicenter, prospective, open-label study of tolterodine extended-release 4\u2003mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT)","volume":"24","author":"Siami","year":"2002","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00192-002-1009-0","article-title":"A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder","volume":"14","author":"Swift","year":"2003","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(02)00177-X","article-title":"Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder","volume":"41","author":"Kreder","year":"2002","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1532-5415.2002.50203.x","article-title":"Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients","volume":"50","author":"Zinner","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2005.02.024","article-title":"The effects of antimuscarinic treatments in overactive bladder: A systematic review and meta-analysis","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0090-4295(02)01784-3","article-title":"Definition and epidemiology of overactive bladder","volume":"60","author":"Wein","year":"2002","journal-title":"Urology"},{"issue":"Suppl. 2","key":"10.1111\/j.1742-1241.2006.00986.x-BIB26|cit26","first-page":"25","article-title":"Assessing the impact of urinary incontinence in a female population","volume":"32","author":"Costa","year":"1997","journal-title":"Eur Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-5347(01)65075-4","article-title":"The International Continence Society \u2018\u2018Benign Prostatic Hyperplasia\u2019\u2019 Study: the bothersomeness of urinary symptoms","volume":"157","author":"Peters","year":"1997","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.urology.2003.09.070","article-title":"Comparative analysis of lower urinary tract symptoms and bother in both sexes","volume":"63","author":"Terai","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0022-5347(01)64955-3","article-title":"The International Continence Society \u2018\u2018Benign Prostatic Hyperplasia\u2019\u2019 Study: international differences in lower urinary tract symptoms and related bother","volume":"157","author":"Witjes","year":"1997","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0090-4295(03)00037-2","article-title":"American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life","volume":"61","author":"Scarpero","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1532-5415.2002.50115.x","article-title":"Urinary incontinence and psychological distress in community-dwelling older adults","volume":"50","author":"Bogner","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/nau.2093","article-title":"Bother arising from urinary frequency in women","volume":"21","author":"FitzGerald","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2006.00986.x-BIB33|cit33","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316771","volume-title":"Statistical Intervals: A Guide for Practitioners","author":"Hahn","year":"1991"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.00986.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.00986.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:26Z","timestamp":1643349866000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.00986.x"}},"subtitle":["IMPACT: TOLTERODINE IMPROVES BOTHERSOME OAB SYMPTOMS"],"short-title":[],"issued":{"date-parts":[[2006,5,24]]},"references-count":33,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.00986.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,24]]}}}